- Home
- REGN vs PBR Comparison
REGN vs PBR Comparison
Compare REGN & PBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | PBR |
|---|---|---|
| Founded | 1988 | 1953 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.9B | 78.3B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | REGN | PBR |
|---|---|---|
| Price | $755.77 | $12.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 2 |
| Target Price | ★ $795.74 | $14.85 |
| AVG Volume (30 Days) | 1.1M | ★ 15.7M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | 0.47% | ★ 13.85% |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 41.59 | 1.13 |
| Revenue | $14,247,800,000.00 | ★ $92,214,132,772.00 |
| Revenue This Year | $1.95 | $2.77 |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $17.82 | ★ $10.79 |
| Revenue Growth | ★ 2.89 | N/A |
| 52 Week Low | $476.49 | $11.03 |
| 52 Week High | $790.98 | $14.98 |
Technical Indicators
Market Signals| Indicator | REGN | PBR |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 43.00 |
| Support Level | $689.88 | $12.12 |
| Resistance Level | $753.61 | $12.36 |
| Average True Range (ATR) | 20.54 | 0.25 |
| MACD | -4.09 | -0.07 |
| Stochastic Oscillator | 65.15 | 13.89 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2024 was 2.7 million barrels of oil equivalent a day (80% oil production), and reserves stood at 11.4 billion boe (85% oil). At end-2024, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.